• To determine the potential utility of antigen-specific immune complex analysis, we developed a competitive enzyme-linked immunosorbent assay utilizing polyclonal human antibody to detect tumor-associated antigen-specific immune complexes. Sera from 10 normal volunteers and 19 patients with recurrent melanoma were studied. Patients with recurrent melanoma had a mean ± SD percent inhibition of 27.6% ± 29.8% in contrast to normal individuals with a mean value of 8.4% ± 17.8%. A monoclonal antibody (MAb JSI) was developed following immunization with a partially purified antigen. Utilizing MAb JSI, we developed a "sandwich" enzyme-linked immunosorbent assay and studied sera from 45 normal volunteers and 44 patients with cancer with recurrent melanoma. Results were expressed as a percent maximum binding of a positive control. The mean ± SD percent maximum binding for normal subjects was 4.9% ± 7.7% in contrast to sera from patients with melanoma who had a mean of 38.3% ±33.3%. Serial analysis of four patients with melanoma with tumor-associated antigen-specific immune complexes demonstrated the presence of tumor-associated antigen-specific immune complexes up to 12 years prior to clinical recurrence.
(Arch Surg. 1990;125:187-191)
Wong JH, Xu S, Gupta RK, Morton DL. Tumor-Associated Antigen Immune Complexes: A Potential Marker of Recurrent Melanoma. Arch Surg. 1990;125(2):187–191. doi:10.1001/archsurg.1990.01410140065011
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: